<DOC>
	<DOCNO>NCT00788892</DOCNO>
	<brief_summary>The study investigate CPX-351 ) effective standard AML treatment b ) tolerable standard AML treatment regimen . The study compare investigational product CPX-351 vs standard treatment AML patient age group .</brief_summary>
	<brief_title>Trial CPX-351 Newly Diagnosed Elderly AML Patients</brief_title>
	<detailed_description>This study randomize , open-label , parallel-arm , fixed-dose , standard therapy control Phase IIB trial . Study enrollment duration expect approximately 12-18 month . On entry , patient randomize receive either CPX-351 standard induction treatment cytarabine daunorubicin ( `` 7 3 '' regimen ) . Patients stratify balance likelihood obtain CR duration CR two arm .</detailed_description>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<criteria>Age ≥60 &lt; 76 year time diagnosis AML Pathological confirmation AML Eastern Cooperative Oncology Group ( ECOG ) performance status 02 Able adhere study visit schedule protocol requirement Laboratory value fulfil follow : Serum creatinine &lt; 2.0 mg/dL Serum total bilirubin &lt; 2.0 mg/dL Serum alanine aminotransferase aspartate aminotransferase &lt; 150 IU/liter Note : If elevate liver enzymes related disease ; contact medical monitor discus . Cardiac ejection fraction &gt; 50 % echocardiography MUGA scan Patients locally advance metastatic solid tumor ≤5 year initial diagnosis exclude . ( Patients locally advanced metastatic solid tumor &gt; 5 year initial diagnosis , investigator clinical suspicion active disease &gt; 2 year randomization eligible ) Prior treatment AML ; hydroxyurea permit ( see ) Acute promyelocytic leukemia [ ( 15 ; 17 ) ] favorable cytogenetics , include ( 8 ; 21 ) inv16 know time randomization Patients prior anthracycline exposure great 368 mg/m2 daunorubicin ( equivalent ) Any serious medical condition , laboratory abnormality psychiatric illness would prevent obtain informed consent Administration antineoplastic therapy within 4 week first CPX351 dose ; event rapidly proliferative disease use hydroxyurea permit 24 hour start study treatment Clinical evidence active CNS leukemia Patients history and/or current evidence myocardial impairment ( e.g . cardiomyopathy , ischemic heart disease , significant valvular dysfunction , hypertensive heart disease , congestive heart failure ) result heart failure New York Heart Association Class III IV stag Active uncontrolled infection . Patients infection receive treatment antibiotic may enter study afebrile hemodynamically stable 72 hr . Current evidence invasive fungal infection ( blood tissue culture ) ; HIV active hepatitis C infection Hypersensitivity cytarabine , daunorubicin liposomal product History Wilson 's disease copperrelated disorder</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Acute</keyword>
	<keyword>Myeloid</keyword>
	<keyword>Leukemia</keyword>
	<keyword>elderly</keyword>
	<keyword>Newly</keyword>
	<keyword>Diagnosed</keyword>
</DOC>